Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine-Reference-Cited by-同舟云学术

Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine

Published:2018-04 Issue:4 Volume:29 Page:295-306
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Church Kevin J.,Vanderwerff Brett R.,Riggers Rachelle R.,Mateo-Victoriano Beatriz,Fagnan Matthew,Harris Phillip H.,LeValley Jewel C.,Harding Joseph W.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference44 articles.

1. Cancer statistics, 2015;Siegel;CA Cancer J Clin,2015

2. Pancreatic cancer;Vincent;Lancet,2011

3. Pancreatic carcinoma in perspective. A continuing challenge;Wanebo;Cancer,1996

4. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

5. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer;De Sousa Cavalcante;Eur J Pharmacol,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF‐PU.1‐DPP4 Axis;Advanced Science;2021-08-10

2. Macrophage-stimulating protein is decreased in severe preeclampsia and regulates the biological behavior of HTR-8/SVneo trophoblast cells;Placenta;2021-01

3. Hepatocyte Growth Factor and Macrophage-stimulating Protein “Hinge” Analogs to Treat Pancreatic Cancer;Current Cancer Drug Targets;2019-12-23